Literature DB >> 759000

A collaborative study of infective endocarditis in the 1970s. Emphasis on infections in patients who have undergone cardiovascular surgery.

E L Kaplan, H Rich, W Gersony, J Manning.   

Abstract

Twenty-six major cardiovascular centers participated in a cooperative study of all cases of infective endocarditis occurring during a single calendar year to obtain an overview of infective endocarditis. The study was designed to learn which patients appear to be at highest risk to develop this infection after palliative or reparative cardiovascular surgery. Of 278 patients developing infective endocarditis during the year at these medical centers, 63 (23%) had had previous cardiovascular surgery and 215 had not. Seventy percent of the 278 patients had recognized congenital or acquired heart disease before developing the infection. Rheumatic heart disease accounted for over half of the patients with underlying structural heart disease. A majority (55%) of the 63 patients who had been operated on before developing endocarditis had prosthetic valves inserted. Of those who did not require prosthetic valves, the majority had congenital heart disease with systemic artery-to-pulmonary artery shunts. Although these data were obtained from a selected group of patients, they confirm a significant risk of endocarditis in patients with prosthetic valves and suggest that in postoperative patients with non-valvular congenital heart disease, the highest risk appears to be in cyanotic patients with palliative pulmonary artery-to-systemic artery shunts.

Entities:  

Mesh:

Year:  1979        PMID: 759000     DOI: 10.1161/01.cir.59.2.327

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  10 in total

1.  Survival into sixth decade after a Potts palliation for Tetralogy of Fallot, complicated by shunt-infective endocarditis and massive pulmonary embolism.

Authors:  Lucy Cosbey; Tamara Naneishvili; Adrian Morley-Davies; Hefin Jones
Journal:  BMJ Case Rep       Date:  2019-04-24

2.  Current clinical aspects of bacterial endocarditis in infancy, childhood, and adolescence.

Authors:  H H Kramer; M Bourgeois; R Liersch; H Kuhn; L Nessler; H Meyer; G Sievers
Journal:  Eur J Pediatr       Date:  1983 Jun-Jul       Impact factor: 3.183

Review 3.  Gastrointestinal instrumentation, bacteraemia, and endocarditis.

Authors:  P J Shorvon; S J Eykyn; P B Cotton
Journal:  Gut       Date:  1983-11       Impact factor: 23.059

4.  Infective endocarditis in congenital heart disease: Japanese national collaboration study.

Authors:  K Niwa; M Nakazawa; S Tateno; M Yoshinaga; M Terai
Journal:  Heart       Date:  2005-06       Impact factor: 5.994

5.  Ingestion of Staphylococcus aureus by bovine endothelial cells results in time- and inoculum-dependent damage to endothelial cell monolayers.

Authors:  J M Vann; R A Proctor
Journal:  Infect Immun       Date:  1987-09       Impact factor: 3.441

6.  Surgical management of native valve endocarditis.

Authors:  T Raychaudhury; A Faichney; E W Cameron; P R Walbaum
Journal:  Thorax       Date:  1983-03       Impact factor: 9.139

7.  Infective endocarditis in childhood.

Authors:  G F Sholler; R E Hawker; J M Celermajer
Journal:  Pediatr Cardiol       Date:  1986       Impact factor: 1.655

8.  Surgical treatment of infective endocarditis with special reference to prosthetic valve endocarditis.

Authors:  S Westaby; C Oakley; R N Sapsford; H H Bentall
Journal:  Br Med J (Clin Res Ed)       Date:  1983-07-30

9.  Infective endocarditis in congenital heart disease: a frequent community-acquired complication.

Authors:  J Fortún; T Centella; P Martín-Dávila; M J Lamas; C Pérez-Caballero; L Fernández-Pineda; E Otheo; J Cobo; E Navas; V Pintado; E Loza; S Moreno
Journal:  Infection       Date:  2012-09-07       Impact factor: 3.553

Review 10.  New aspects of staphylococcal infections: emergence of coagulase-negative staphylococci as pathogens.

Authors:  A Fleer; J Verhoef
Journal:  Antonie Van Leeuwenhoek       Date:  1984       Impact factor: 2.271

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.